Hennigsdorf, Germany

Karin Vollhardt

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Revotar Biopharmaceuticals Ag. Active years: 2011.

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Karin Vollhardt

Introduction

Karin Vollhardt is a notable inventor based in Hennigsdorf, Germany. She has made significant contributions to the field of pharmaceuticals through her innovative work. Her research focuses on the development of novel crystalline forms that have practical applications in medicine.

Latest Patents

Karin Vollhardt holds a patent for "Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-α-D-mannopyranosyloxy)-phenyl] hexane." This patent describes the novel crystalline and polymorphic forms of the compound, which exhibit advantageous properties. These forms can be utilized in pharmaceutical and dermatological compositions, highlighting their potential impact on healthcare.

Career Highlights

Throughout her career, Karin has demonstrated a commitment to advancing pharmaceutical science. Her work has led to the development of innovative solutions that address various medical needs. She is currently associated with Revotar Biopharmaceuticals AG, where she continues to contribute to groundbreaking research.

Collaborations

Karin has collaborated with esteemed colleagues, including Ewald Aydt and Remo Kranich. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Karin Vollhardt's contributions to the field of pharmaceuticals through her innovative patents and collaborative efforts underscore her importance as an inventor. Her work continues to pave the way for advancements in medical treatments and applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…